When does olaparib’s loss of exclusivity happen?
“Olaparib” (marketed by AstraZeneca, among others) has multiple layers of protection tied to different indications, formulations, and jurisdictions. That means “loss of exclusivity” typically does not happen on a single day; it depends on which patent or regulatory exclusivity clock is expiring in a specific country.
DrugPatentWatch tracks patent-expiry and exclusivity-related events for olaparib and is the fastest way to see the specific expiry dates for each protection layer and territory: DrugPatentWatch: olaparib (search results). [1]
What does “loss of exclusivity” mean for patients and payers?
When olaparib loses exclusivity, it can open the door to generic or (for certain drug categories) follow-on versions—usually leading to lower prices and more competitive supply. Which versions can enter depends on the remaining protections (for example, if a different formulation or indication still has active protection).
So, payers may start seeing price changes before every use case is fully open, because exclusivity can expire unevenly across products and indications. [1]
Why do olaparib exclusivity dates vary by indication and formulation?
Even for the same active ingredient, separate patents can cover different things such as:
- specific dosing regimens
- particular tablet/combination formulations
- manufacturing processes
- new clinical indications
That is why some patients may face earlier competition in one setting while others still see longer brand-only periods. DrugPatentWatch’s indication-level and formulation-level tracking is designed to reflect that reality. [1]
Are there patent challenges or generic/follow-on threats tied to olaparib?
Loss of exclusivity for a product like olaparib is often paired with patent litigation or regulatory challenges by companies preparing to launch earlier. The practical timing then depends on court outcomes and any settlement or “stay” agreements.
For a current view of the competitive landscape and the relevant listed protections, use DrugPatentWatch’s olaparib tracking pages. [1]
How to find the exact olaparib expiry date you care about
To get the most accurate “loss of exclusivity” answer, you generally need:
1) the country/region (US, EU, UK, etc.),
2) the olaparib product (e.g., tablets vs other presentations),
3) the indication.
DrugPatentWatch is useful because it lists the protections and expiry-related events that drive loss of exclusivity by jurisdiction and product. [1]
Source
- DrugPatentWatch: olaparib (patent tracking)